Background-Chronic elevations in circulating C-reactive protein (CRP) are associated with a greater risk of hypertension.
C
-reactive protein (CRP) is an acute-phase reactant that has been shown to be a predictor of the risk of myocardial infarction in apparently healthy individuals. More recently, numerous epidemiological studies have also demonstrated that minor elevations in CRP levels are associated with increased risk of hypertension. [1] [2] [3] Although such observations implicate a role for CRP in the pathogenesis of hypertension, CRP elevation may instead be the result of vascular injury induced by high blood pressure (BP). Alternatively, elevations in proinflammatory cytokines or acutephase reactants other than CRP may contribute to the development of hypertension, and the increase in CRP is an epiphenomenon. Thus, it is presently unknown whether CRP directly causes hypertension.
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The purpose of the present study was to test the hypothesis that chronic CRP elevation induces hypertension in mice. We measured conscious BP by radiotelemetry in wild-type CF1 control and CF1 transgenic mice expressing rabbit CRP under the regulation of the phosphoenolpyruvate carboxykinase promoter (CF1-CRP). 4 Because mice express low levels of CRP (Ͻ2 g/mL) even in the presence of acute inflammation, 5 CRP in the CF1-CRP mouse is derived primarily from expression of the transgene. Use of the CF1-CRP mice with transgene expression controlled by the phosphoenolpyruvate carboxykinase promoter provides a reliable means to upregulate and downregulate CRP levels independent of other mediators of immune response via manipulations of carbo-hydrate intake. 4 Along with testing the primary hypothesis, experiments were designed to answer the following questions: (1) Is BP sensitive to both increases and decreases in circulating CRP levels? (2) What is the threshold concentration of circulating CRP in mice that induces hypertension? (3) How does CRP modulate BP?
Methods

Animal Model
Experiments were performed in CF1-CRP mice that express a transgene consisting of the protein-coding region of the rabbit CRP gene linked to the promoter/regulatory region of the rat phosphoenolpyruvate carboxykinase gene. 6 Additional details, including the manipulation of transgene expression by diet, 6 are in the online-only Data Supplement.
Chronic BP Measurements
Chronic, conscious BP measurements were performed by radiotelemetry as described in the online-only Data Supplement. 7 Baseline BP recordings were averaged over a 4-day period on standard chow. The diet was changed to high-carbohydrate chow to dampen transgene expression, and BP was measured over 3 days beginning 4 days after the diet change. The diet was then switched to carbohydratefree chow to activate transgene expression, and BP was measured over 3 days beginning 4 days after the diet change. To assess BP responses to angiotensin II or norepinephrine, an osmotic minipump (Alzet model 2002; Cupertino, Calif) containing angiotensin II or norepinephrine (Sigma, St Louis, Mo) was implanted in a subcutaneous pocket in the right flank under anesthesia and left in place for 14 days. Angiotensin II was administered at 400 ng/kg per minute, and norepinephrine was given at 1800 ng/kg per minute. To assess the impact of angiotensin receptor subtype 1 (AT 1 ) antagonism, telmisartan was administered for 7 days at 2 mg/kg per day in the drinking water. As was done with the dietary manipulations, BP responses to angiotensin II, norepinephrine, or telmisartan were averaged over the last 3 days of each treatment.
Plasma Renin Activity
Mouse plasma (8 L) was incubated at 37°C with and without the addition of an excess of rat angiotensinogen purified from bilaterally nephrectomized rats. Conversion of angiotensin I to angiotensin II was inhibited by the addition of EDTA (0.02 mol/L). Angiotensin I was measured by radioimmunoassay by previously established methods and a commercially available kit (DiaSorin, Stillwater, Minn). 8 
CRP Assays
Circulating levels of rabbit CRP were measured in 10 L of serum collected by retro-orbital sampling by ELISA as previously described. 9, 10 
Ex Vivo Artery Incubations
Thoracic aortas were harvested and incubated in serum-free, phenol red-free Dulbecco's modified Eagle's medium (DMEM) gassed with 95% O 2 for 6 hours at 37°under sterile conditions. Treatment groups were as follows: DMEM alone (control), DMEM with human recombinant CRP (50 g/mL, Calbiochem, EMD Biosciences, Inc, San Diego, Calif), and DMEM plus CRP plus S-nitroso-N-acetyl penicillamine (SNAP) (100 mol/L). Two aortas were pooled per treatment group.
Measurement of AT 1 and AT 2 mRNA Abundance
RNA was isolated from thoracic aortas, and reverse-transcription and real-time polymerase chain reaction was performed for AT 1 and angiotensin receptor subtype 2 (AT 2 ) as described in the online-only Data Supplement.
Measurement of AT 1 and AT 2 Protein Abundance
AT 1 and AT 2 protein abundance in thoracic aortas was evaluated by immunoblot analysis (see the online-only Data Supplement). Additional experiments were performed with aortas from CF1 mice treated with N G -nitro-L-arginine methyl ester (L-NAME) in the drinking water at the dose of 100 mg/kg per day for 14 days. This dose of L-NAME causes an increase in BP in mice to the level equivalent to BP found in endothelial NO synthase-null mice, 11 and such an elevation in BP was confirmed by radiotelemetry in additional instrumented CF1 mice.
Statistical Methods
Results are expressed as meanϮSEM. All statistical analyses were performed with SAS version 9.1.3 (SAS Institute, Cary, NC). Additional details are provided in the online-only Data Supplement. PϽ0.05 was considered statistically significant.
The authors had full access to and take responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results
Effect of CRP on BP
To first determine whether CRP affects BP, we performed chronic BP measurements by radiotelemetry in 12-to 16-week-old male CF1 control versus CF1-CRP mice on standard chow. Whereas CRP levels were Ͻ1 g/mL in CF1 controls, CF1-CRP mice had CRP levels of 45Ϯ3 g/mL. Systolic BP was higher in CF1-CRP mice than in CF1 controls ( Figure 1A) , diastolic BP was similar ( Figure 1B) , and pulse pressure ( Figure 1C ) and mean BP were also higher in CF1-CRP mice than in CF1 controls (122Ϯ4 versus 110Ϯ1 mm Hg, respectively; PϽ0.05). In contrast, heart rate and the levels of activity of the mice were similar ( Figure 1D , 1E). These findings indicate that CRP causes hypertension in mice and that it is primarily systolic hypertension.
To determine whether BP is sensitive to either declines or elevations in circulating CRP levels, alterations in BP with dietary manipulation of transgene expression were investigated. BP was measured by radiotelemetry over a 4-day period on standard chow, the diet was changed to highcarbohydrate chow to dampen transgene expression, and BP was measured over a 3-day period beginning 4 days after the diet change. The diet was then changed to a carbohydratefree, protein-rich chow to activate transgene expression, and BP was measured over a 3-day period beginning 4 days after the diet change. Neither systolic nor diastolic BP was altered by the diet changes in CF1 control mice in which CRP levels were Ͻ1 g/mL under all conditions (Figure 2A ). In contrast, in CF1-CRP mice, systolic BP fell by 12 mm Hg when CRP was lowered from 45Ϯ3 to 19Ϯ1 g/mL by placement on the high-carbohydrate diet, and it rose by 11 mm Hg when CRP levels were then increased to 123Ϯ15 g/mL by placement on the carbohydrate-free diet ( Figure 2B ). Diastolic BP in CF1-CRP mice remained unchanged when CRP levels were lowered by the high-carbohydrate diet but increased by 9 mm Hg when CRP was elevated by the carbohydrate-free diet. These findings indicate that there are marked alterations in BP, particularly in systolic BP, within days of either declines or elevations in CRP that parallel the changes in CRP.
To gain greater insight into the threshold level of CRP that affects BP in mice, CF1-CRP transgenic mice were mated with CF1 mice, and CRP levels and BP were evaluated in the offspring that were hemizygous for the transgene (designated CF1-CRP-low). When compared with CF1 controls, the CF1-CRP-low mice on either the standard diet with CRP levels of 15Ϯ5 g/mL or the high-carbohydrate diet with CRP levels of 9Ϯ4 g/mL had elevated systolic BP ( Figure  2C ). In contrast, diastolic BP did not differ between the 3 groups ( Figure 2D ). Thus, even a modest elevation in CRP, comparable to that observed in otherwise healthy humans without active infection or inflammation, 12 is sufficient to induce hypertension in mice. All ensuing studies were performed in CF1-CRP-low mice to evaluate the underlying mechanisms in the setting of minor elevations in CRP.
Effect of CRP on BP Responses to Angiotensin II
To determine the mechanism(s) underlying CRP-induced hypertension, plasma renin concentrations were measured, and BP responses to angiotensin II (400 ng/kg per minute) and norepinephrine (1800 ng/kg per minute) administration via osmotic minipump were compared in CF1 control and CF1-CRP-low mice. Plasma renin activity was not elevated in CF1-CRP-low mice compared with CF1 controls (27.0Ϯ2.0 versus 50.9Ϯ11.2 ng/mL per hour, respectively; PϾ0.05). Angiotensin II caused a larger increase in systolic BP from baseline in CF1-CRP-low mice than in CF1 controls (30Ϯ8 versus 8Ϯ4 mm Hg, respectively; Pϭ0.01). The percentage increase in systolic BP from baseline with angiotensin II was also greater in CF1-CRP-low versus CF1 control mice (Figure 3A) . Angiotensin II tended to increase diastolic BP to a greater extent in CF1-CRP-low mice than in CF1 controls (25Ϯ9 versus 7Ϯ2 mm Hg, respectively; Pϭ0.06). The percentage increase in diastolic BP with angiotensin II also tended to be greater in CF1-CRP-low mice (Pϭ0.06; Figure  3B ). In contrast, norepinephrine caused a similar rise in systolic BP and in diastolic BP from baseline in CF1-CRPlow versus CF1 control mice (15Ϯ3 versus 15Ϯ5 mm Hg for systolic BP and 5Ϯ2 versus 8Ϯ3 mm Hg for diastolic BP, respectively; PϭNS). As a result, relative increases in systolic BP and in diastolic BP from baseline with norepinephrine were not affected by CRP status ( Figure 3C , 3D). Thus, CRP causes a selective increase in BP sensitivity to angiotensin II.
To determine the basis for the exaggerated BP response to angiotensin II with CRP, we compared changes in BP with the oral administration of the AT 1 antagonist telmisartan (2 mg/kg per day) in the CF1-CRP-low and CF1 control mice. Telmisartan caused reductions in systolic BP and diastolic BP in both groups, and the percentage decreases in both systolic and diastolic BP were not affected by CRP status (Figure 3E , 3F). These cumulative in vivo findings reveal that CRP causes a selective increase in BP sensitivity to angiotensin II in the absence of alterations in AT 1 -mediated responses, suggesting that CRP-induced hypertension is related to an effect on AT 2 function.
Effect of CRP on Vascular Angiotensin Receptor Expression
To elucidate the basis for enhanced sensitivity to angiotensin II, vascular angiotensin receptor expression was evaluated in studies of thoracic aortas isolated from CF1 control and CF1-CRP-low mice. Relative abundance of mRNA for the angiotensin receptor subtype 1a (AT 1a ), subtype 1b (AT 1b ), and subtype 2 (AT 2 ) was determined by real-time reversetranscription polymerase chain reaction. Whereas AT 1a and AT 1b transcript abundance was similar in the control and CF1-CRP-low groups ( Figure 4A , 4B), AT 2 mRNA expression was decreased by 98% in the aortas of CF1-CRP-low mice ( Figure 4C ). In parallel, total AT 1 protein expression was similar in the control and CF1-CRP-low groups ( Figure  4D , 4E), whereas AT 2 protein abundance was decreased by 48% in the aortas of CF1-CRP-low mice ( Figure 4F , 4G) (see also Figure I in the online-only Data Supplement). Thus, vascular AT 2 expression is downregulated by CRP in vivo.
To determine whether the reduction in AT 2 in CF1-CRPlow mice is a direct effect of CRP on the vasculature, ex vivo experiments were performed with thoracic aortas from CF1 mice. Aortas were incubated under control conditions or in the presence of CRP for 6 hours, and angiotensin receptor expression was evaluated. Whereas CRP had no effect on AT 1 abundance ( Figure 5A , 5B), AT 2 abundance was decreased by 74% ( Figure 5C, 5D ) (see also Figure II in the online-only Data Supplement), which paralleled the in vivo findings ( Figure 4D to 4G) . CRP that was heat-inactivated by previously described methods 13 did not alter AT 2 expression (87Ϯ17% of control treatment with media alone; nϭ4; Pϭ0.53), indicating that potential nonprotein components of the CRP preparation, such as sodium azide or endotoxin, do not underlie the ex vivo findings. Thus, CRP directly reduces vascular AT 2 receptor expression, and the changes in receptor abundance in vivo are not the consequence of CRP-induced BP elevation or CRP-induced systemic neurohormonal or immune responses.
We recently demonstrated that CRP causes potent inhibition of the activation of endothelial NO synthase in cultured endothelial cells, in mouse arteries studied ex vivo, and in mice in vivo. 13 We therefore performed additional ex vivo incubations of aortas to determine whether CRP-induced changes in AT 2 abundance are due to declines in bioavailable NO. Whereas AT 1 expression remained unaltered ( Figure 5A , 5B), concomitant incubation with the NO donor SNAP attenuated the reduction in AT 2 caused by CRP ( Figure 5C , 5D).
To determine whether NO modulation of vascular AT 2 expression also occurs in vivo, CF1 mice were administered the NO synthase antagonist L-NAME (100 mg/kg per day orally) for 2 weeks, and angiotensin receptor expression was Systolic and diastolic BP (SBP, DBP) were measured by radiotelemetry in (A) CF1 mice (nϭ6) and (B) CF1-CRP mice (nϭ8) over a 4-day period on standard chow; the diet was changed to highcarbohydrate (CHO) chow, and BP was measured over a 3-day period beginning 4 days after the diet change; the diet was then switched to a carbohydrate-free chow, and BP was measured over a 3-day period beginning 4 days after the switch. assessed in the thoracic aorta. Whereas there was no effect of decreasing NO bioavailability on AT 1 ( Figure 6A , 6B), L-NAME treatment caused a 70% reduction in AT 2 protein abundance ( Figure 6C, 6D ) (see also Figure III in the online-only Data Supplement). These cumulative findings indicate that CRP downregulates vascular AT 2 expression and that this is due to a CRP-induced decline in bioavailable NO.
Discussion
Circulating levels of CRP are an independent predictor of the risk of hypertension. [1] [2] [3] However, the role of CRP in the pathogenesis of hypertension is not known. In the present study we have demonstrated that CRP causes a sustained increase in BP in mice and that it is primarily systolic hypertension. In addition, we have shown that the increase in BP induced by CRP is related to an augmented pressor response to angiotensin II that is associated with a reduction in vascular AT 2 expression. These findings provide the first causal linkage between elevations in CRP, the renin-angiotensin system, and hypertension. In previous studies of CRP and hypertension, the shortterm infusion of CRP in mice and humans had no effect on BP. 14 However, vehicle and contaminants found in CRP preparations such as endotoxin and sodium azide can have direct effects on vascular cells and can cause vasodilation and hypotension, [15] [16] [17] and they may have interfered with the potential impact of CRP on BP. Other experiments performed in CRP transgenic mice on an apolipoprotein E-null background revealed no effect of CRP on BP. 18 Variability in intermittent BP measurements with the tail-cuff technique and stress imposed on the animals by restraint may have limited the ability to detect differences in BP in this study. 19, 20 The present investigation has the advantages that CRP levels were regulated by a transgene such that possible complicating variables introduced by the short-term administration of CRP preparations were avoided and that BP was measured chronically and continuously in a large number of unrestrained mice with the use of radio transmitters.
In addition to demonstrating systolic hypertension in CF1-CRP transgenic mice on standard chow, we showed that fluctuation in CRP levels obtained by modifying transgene activation via changes in dietary carbohydrate content resulted in parallel alterations in BP. Because the identical dietary manipulations had no effect on BP in CF1 control mice lacking the transgene, the alterations in BP were due to CRP and not other factors. With a coefficient of variation of 1.3% for systolic BP in CF1-CRP mice on the initial standard diet, the reduction in systolic BP of 12 mm Hg (or 6%) after conversion to a high-carbohydrate diet is not likely explained by spontaneous variation in BP or carryover effect of the initial diet and CRP levels. The comparable rise in systolic BP of 11 mm Hg (or 6%) on switching from a highcarbohydrate to a carbohydrate-free diet is also unlikely to be due to carryover because it is an absolute reversal of the prior fall in BP on placement on a high-carbohydrate diet. Further studies of hemizygous transgenic mice (CF1-CRP-low) indicated that elevated BP occurs in mice with CRP levels in the range of 9 g/mL. In addition, the "dose response" of systolic BP to CRP that was observed with concentrations of Ͻ1 versus 9 versus 15 g/mL suggests that systolic BP would likely be elevated above normal with CRP levels of Ն3 g/mL, which represents the high-risk range for CRP. 12 These cumulative findings indicate that BP modulation by CRP occurs over a period of days, that CRP-induced hypertension can be reversed if CRP levels are lowered, and that it occurs at modest plasma concentrations that are comparable to those observed in otherwise healthy humans without known acute inflammation or infection. 12 In studies aimed at elucidating the mechanisms by which CRP increases BP, a selective increase in BP sensitivity to angiotensin II was demonstrated in the CRP transgenic mice. However, AT 1 antagonism with telmisartan yielded comparable declines in BP in transgenic and control mice, indicating that the exaggerated sensitivity to angiotensin II in the former is not mediated by AT 1 . In parallel experiments, vascular AT 1 expression was not altered by CRP, whereas both mRNA and protein abundance for AT 2 were diminished. These findings contrast with those of previous studies limited to cultured vascular smooth muscle cells that indicated that CRP upregulates AT 1 . 21 However, the present observations in freshly isolated aortas are more likely to represent receptor status in vivo because vascular smooth muscle cell phenotype can change in culture. 22 Although not observed in all prior studies of genetic knockdown of AT 2 , the loss of AT 2 has been found to cause an elevation in basal BP in both mice and rats. [23] [24] [25] In Sprague-Dawley rats in which AT 2 knockdown was accomplished by administering AT 2 antisense cDNA in the neonatal period, primarily basal systolic BP was increased during adulthood. 25 Mice and rats with AT 2 deficiency have uniformly exhibited exaggerated increases in BP in response to angiotensin II infusion, [23] [24] [25] whereas the BP response to AT 1 blockade in mice with AT 2 deficiency is identical to that of wild-type mice. 23 Thus, multiple characteristics of the hypertension phenotype of the CRP transgenic mice mimic those of genetic AT 2 deficiency. When combined with our finding of CRP-induced vascular AT 2 downregulation, these observations suggest that the hypertension in the CRP trans- genic mice is explained by the reduction in vascular AT 2 . In addition to blunting vasoconstrictor response to angiotensin II, AT 2 receptors protect against hypertension by inhibiting renin synthesis and angiotensin II production in the kidneys. 26 However, elevated renin and angiotensin are not likely to contribute to the hypertension in the CRP transgenic mice because plasma renin concentrations were similar to those in controls. As such, the primary defect is likely the reduction in vascular AT 2 .
In parallel with our finding that CRP induces primarily systolic hypertension and increased pulse pressure in mice, in certain epidemiological studies CRP levels have been associated specifically with elevated pulse pressure and systolic BP. 27, 28 The mechanism(s) by which the observed changes in AT 2 induced by CRP lead to systolic hypertension in our study is yet to be elucidated. An accelerated age-related decline in aortic distensibility has been implicated in the pathogenesis of isolated systolic hypertension, 29 which is the most common subtype of hypertension in humans after the age of 50 years, 30 and CRP levels increase gradually with aging in humans. 31, 32 One recent study in rats indicated that the stimulation of AT 2 decreases vascular stiffness by increasing elastin deposition in the vascular wall. 33 Whether the reduction in aortic AT 2 in the CRP transgenic mice results in a loss of elastic tissue and impaired aortic distensibility or whether there is greater angiotensin II-related vascular remodeling in resistance arteries 33 remains to be evaluated. In addition, because the AT 2 receptor also modulates BP by actions in the adrenal gland 34 and central nervous system, 35 further investigations of nonvascular mechanisms in CF1-CRP mice are now warranted. Along with the experiments demonstrating CRP-mediated downregulation of vascular AT 2 in vivo, studies were performed to determine the underlying mechanism(s). It is more likely that the loss of vascular AT 2 is a primary event and not secondary to the hypertension because studies of distal aortic banding in rats indicate that pressure overload increases AT 2 expression in the thoracic aorta. 36 We performed ex vivo incubations of mouse thoracic aortas with recombinant human CRP, which has characteristics very similar to those of rabbit CRP based on both in vivo and in vitro studies. Both are acute-phase reactants in their species, they rise and then fall after an inflammatory stimulus in a similar manner and at comparable concentrations, they activate complement and bind to phosphocholine, and their binding characteristics and the structural features underlying their binding characteristics are shared. 37 In the ex vivo experiments, CRP caused AT 2 downregulation, whereas AT 1 expression was unaltered, paralleling the in vivo findings. These results indicate that systemic processes, including immune response mechanisms such as complement activation, are not required for CRP modulation of vascular AT 2 . Alternatively, the effect of CRP on AT 2 occurs via direct action(s) on vascular cells. Further ex vivo experiments showed that the NO donor SNAP blunted the CRP-induced AT 2 downregulation. In parallel, NO-related modulation of vascular AT 2 was demonstrated in vivo in the studies in which NO synthase antagonism in wild-type mice caused a selective loss of vascular AT 2 . When considered along with our prior observation that CRP inhibits the activation of endothelial NO synthase in cultured endothelial cells, in arteries studied ex vivo, and in vivo in mice, 13 these findings indicate that CRP downregulation of vascular AT 2 expression is due to a CRP-induced decline in bioavailable NO. Although previous work investigating AT 2 expression in PC12 cells has demonstrated positive modulation of the receptor by NO-mediated mechanisms, 38 the molecular basis of regulation of AT 2 gene expression by NO is unknown, and detailed, focused studies are now required to elucidate the underlying processes.
The present observations provide the first direct evidence for hypertensive action of CRP, and they identify a novel series of mechanisms by which CRP induces hypertension by causing NO-sensitive downregulation of vascular AT 2 . In doing so, our findings provide important new perspectives on the processes by which a byproduct of chronic inflammation has a direct negative impact on cardiovascular health. In addition, we have identified a new model for isolated systolic hypertension. It is anticipated that further research in this realm will enhance our basic understanding of hypertension associated with inflammation and aging. 
Sources of Funding
Disclosures
Dr Shaul reports having received honoraria for participation in a scientific meeting at which data in this article were discussed. The remaining authors report no conflicts.
